Genesystem Co., Ltd. (KOSDAQ:363250)

South Korea flag South Korea · Delayed Price · Currency is KRW
5,500.00
-340.00 (-5.82%)
At close: Apr 28, 2026
-45.22%
Market Cap 41.64B
Revenue (ttm) 381.36M
Net Income (ttm) -11.96B
Shares Out 7.57M
EPS (ttm) -1,754.00
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 51,558
Average Volume 40,386
Open 6,150.00
Previous Close 5,840.00
Day's Range 5,430.00 - 6,150.00
52-Week Range 3,480.00 - 10,690.00
Beta 0.37
RSI 38.84
Earnings Date Mar 27, 2026

About Genesystem

Genesystem Co., Ltd., a biotech engineering company, specializes in molecular testing solutions to target on-site testing needs. The company offers PCR systems, multiplex biochips, and PCR reagents. It also provides human pathogen assays, including novel coronavirus (SARS-CoV-2) detection kits, SARS-CoV-2/Flu/RSV simultaneous detection kits, and mycobacterium tuberculosis detection kits; veterinary diagnostics; food safety assays comprising foodborne pathogen detection kits, HALAL food testing kits, and meat species identification kits; and nuc... [Read more]

Industry Electromedical and Electrotherapeutic Apparatus
Founded 2010
Employees 54
Stock Exchange KOSDAQ
Ticker Symbol 363250
Full Company Profile

Financial Performance

In 2025, Genesystem's revenue was 381.36 million, a decrease of -68.42% compared to the previous year's 1.21 billion. Losses were -11.96 billion, 34.1% more than in 2024.

Financial Statements

News

There is no news available yet.